Sana Biotechnology Announces Increased Focus on Hypoimmune-R

Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Seattle , Washington , United States , Cambridge , Cambridgeshire , United Kingdom , Steve Harr , Nicole Keith , Sana Biotechnology Inc , Nasdaq , Biotechnology Announces Increased Focus , Hypoimmune Related Pipeline , Deliver Clinical Proof , Concept Data , Four Programs , Burn Guidance , South San Francisco , Sana Biotechnology , Quarterly Report ,